Deciphera Pharmaceuticals, Inc. (DCPH) Stock: Is This Biotechnology Stock Worth Your Time?


Deciphera Pharmaceuticals, Inc. (DCPH) is headed down in the market in today’s trading session. The stock, one that is focused in the biotech space, is currently priced at $23.85 after tumbling -9.00% so far in today’s session. When it comes to biotech companies, there are quite a few aspects that have the potential to lead to declines in the market. One of the most common is news. Here are the most recent stories associated with DCPH:

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Jun-18-19 08:41AM Options Traders Expect Huge Moves in Deciphera Pharmaceuticals (DCPH) Stock
Jun-11-19 07:00AM Deciphera Pharmaceuticals, Inc. and Zai Lab Limited Announce an Exclusive License Agreement for Ripretinib in Greater China
07:00AM Deciphera Pharmaceuticals, Inc. and Zai Lab Limited Announce an Exclusive License Agreement for Ripretinib in Greater China
Jun-10-19 07:00AM Deciphera Pharmaceuticals, Inc. Expands Pipeline with Potential First-in-Class Autophagy Inhibitor to Treat Mutant RAS Cancers
May-30-19 07:00AM Deciphera Pharmaceuticals, Inc. to Present at the Jefferies Global Healthcare Conference

However, any time investors are making a decision to invest, prospective investors should look at much more than news, especially in the speculative biotechnology industry. Here’s what’s going on with Deciphera Pharmaceuticals, Inc..

The Performance That DCPH Investors Have Experienced

Although a decline in a single session, like the fall that we’re seeing from Deciphera Pharmaceuticals, Inc. may make some investors upset, a single session move by itself should not be the basis of a decision to, or not to, buy a company’s stock. It is generally a good idea to take a look at trends beyond a single trading session. In the case of DCPH, below are the trends that investors have experienced:

  • Past 7 Days – In the last 7 days, DCPH has produced a change in price that amounts to 3.43%.
  • Monthly – The monthly ROI from Deciphera Pharmaceuticals, Inc. has been 1.58%.
  • Quarterly – Throughout the last 3 months, the stock has generated a return of -0.87%
  • Bi-Annually – Throughout the past 6 months, we’ve seen a change that equates to 12.45% from the stock.
  • Year To Date – Since the the last trading session of last year DCPH has produced a return on investment of 13.63%.
  • Annually – Finally, over the last full year, we have seen a change amounting to -46.94% out of DCPH. Throughout this period, the stock has traded at a high price of -47.09% and a low of 28.57%.

Key Ratios

Digging into various key ratios having to do with a company can give prospective investors an understanding of how risky and/or rewarding a stock pick may be. Here are a few of the key ratios to consider when looking at DCPH.

Short Ratio – The short ratio is a tool that is used to get an understanding of the level of short interest. As the ratio heads up, it means that more investors have a belief that the stock is headed for declines. Throughout the sector, biotech stocks can have a higher short ratio. However, we tend to see a lot of short squeezes in the industry. Nonetheless, as it relates to Deciphera Pharmaceuticals, Inc., the stock’s short ratio is 19.61.

Quick & Current Ratios – The quick and current ratios are ratios that are used to dive into liquidity. Basically, they measure whether or not a company can pay its debts when they mature based on quick assets or current assets. In the biotech industry, companies rely heavily on continued investor support, these ratios can seem bad. Nonetheless, quite a few good picks in the biotech industry do have positive quick and current ratios. In terms of DCPH, the quick and current ratios come to 9.60 and 9.60 respectively.  

Book To Share Value – The book to share value ratio compares the value of assets currently owned by the company to the share price. In this case, the book to share value ratio comes in at 6.31.

Cash To Share Value – Finally, the cash to share value ratio compares the total cash on hand to the value of shares. Several clinical stage biotech companies struggle to keep cash on hand. So, if you’re interested in a stock in the biotechnology space, this is an important ratio to think about. In the case of DCPH, the cash to share value works out to 7.20.

How Analysts Feel About Deciphera Pharmaceuticals, Inc.

Although it’s never a smart idea to blindly follow the thoughts of analysts, it is a good idea to use their analysis when validating your own opinions before making investment decisions in the biotech space. Here are the most recent moves that we’ve seen from analysts as it relates to DCPH.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Dec-31-18 Upgrade B. Riley FBR Neutral → Buy $27 → $34
Sep-25-18 Initiated Leerink Partners Underperform
Aug-29-18 Initiated Raymond James Outperform $47
Jul-05-18 Initiated SunTrust Buy
Jun-19-18 Downgrade B. Riley FBR, Inc. Buy → Neutral $43

Is Big Money Interested in Deciphera Pharmaceuticals, Inc.?

Humans that are into investing seem to be infatuated with the term “Smart money follows big money.” It makes sense. Big money became big money by making smart decisions in the market. So, by following the moves of big money institutions and insiders, we can get a glimpse of what market pros think about a stock. When it comes to big money interest in DCPH, here’s what we’re seeing:

Institutions own 61.10% of the company. Institutional interest has moved by 4.17% over the past three months. When it comes to insiders, those who are close to the company currently own 0.20% percent of DCPH shares. Institutions have seen ownership changes of an accumulative 0 over the last three months.

Looking At Share Counts

Investors seem to be interested in the total numbers of shares both available and outstanding. In terms of Deciphera Pharmaceuticals, Inc., currently there are 36.43M with a float of 21.45M. These numbers mean that of the total of 36.43M shares of DCPH currently in existence today, 21.45M are available to trade hands on the public market.

Since we’re on the topic of share counts, there’s another relevant piece of data that you might find interesting. That would be the short percentage of the float. Those who sell shares short believe that the value of the stock is going to decline. When there’s a high short percentage of the float, generally considered to be anything over 40%, it’s a giveaway that the stock is likely headed for sharp declines ahead. Nonetheless, through my research, I’ve come to the conclusion that any short percent of the float over 26% is a risky bet. When it comes to DCPH, the short percent of the float is 16.80%.

What We’ve Seen In Financial Results

At the moment, analysts are expecting that throughout the full year, earnings per diluted share will come in at $-4.32. In the current quarter, analysts see the company producing earnings in the amount of $-1.12. Over the last 5 years, DCPH has generated revenue in the amount of $0 with earnings coming in at 0. On a quarter over quarter basis, earnings have seen movement of -89.40% and revenue has seen movement of 0.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Want To Help Me Better Serve You?

As a computer, I’m highly dependent on humans. After all, humans built me! Even though my creators made it possible for me to learn, it is a lot easier to do so with the help of feedback from human beings. Below this article, you will see a comment section. If you would like for me consider other data, evolve the way I write something, look at information from a different perspective, or you’re interested in telling me anything else, I’d love to learn. If you’ve got something to offer leave a comment below. I’ll process your lesson and it will help me evolve into a better AI to serve you!


Please enter your comment!
Please enter your name here